资料显示，哈尔滨三联药业股份有限公司位于黑龙江省哈尔滨市利民开发区北京路，成立日期1996年6 月21日，上市日期2017年9月22日，公司主营业务涉及化学药品制剂的研发、生产和销售。主营业务收 入构成为：大输液32.00%，冻干粉针剂18.39%，固体制剂17.39%，小容量注射剂14.34%，其他(补 充)10.26%，兽药2.55%，进出口贸易1.82%，原料药1.73%，化妆品0.94%，医疗器械0.43%，功能食品 0.16%。 哈三联所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：高血压防治、抗流感、肝 炎治疗、创新药、宠物经济等。 12月18日，哈三联盘中上涨2.10%，截至13:41，报13.15元/股，成交4103.33万元，换手率1.81%，总市 值41.60亿元。 资金流向方面，主力资金净流入46.33万元，大单买入354.33万元，占比8.64%，卖出308.00万元，占比 7.51%。 哈三联今年以来股价涨36.27%，近5个交易日跌1.79%，近20日跌4.29%，近60日跌4.15%。 今年以来哈三联已经9次登上龙虎榜，最近一次登上龙虎榜为6月3日。 截至12月1 ...

在此背景下，公司本次投资设立湖北济民军民科技创新有限公司，是公司基于长远战略规划的重要布 局，核心目的为公司培育和整合优质标的资产，推动公司产业转型升级，增强公司核心竞争力及可持续 发展能力。 公司主营业务涵盖医疗服务、医疗器械和大输液等产品的研发、生产与销售。近年来，受行业竞争加剧 及美国关税政策等外部因素影响，公司整体主营业务承压，业绩出现一定程度的下滑。 格隆汇12月12日丨济民健康(603222.SH)公布，公司拟与湖北省军民科技创新有限公司共同设立合资公 司湖北济民军民科技创新有限公司。投资金额和比例：合资公司注册资本为6亿元，其中，公司认缴出 资2.94亿元，持股比例为49%，军民科技认缴出资3.06亿元，持股比例为51%，各方均以现金出资。 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603367 证券简称：辰欣药业 公告编号：2025-064 辰欣药业股份有限公司 关于2025年第三季度业绩说明会召开情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 辰欣药业股份有限公司（以下简称"公司"或"辰欣药业"）于2025年11月26日上午9:00-10:00在上海证券 交易所上证路演中心（网址：http://roadshow.sseinfo.com）以网络文字互动方式召开了公司2025年第三 季度业绩说明会。就投资者普遍关心和关注的问题进行了互动交流沟通。现将召开情况公告如下： 一、业绩说明会的召开情况 公司于2025年11月21日在上海证券交易所网站（www.sse.com.cn）和信息披露指定媒体披露了《辰欣药 业股份有限公司关于召开2025年第三季度业绩说明会的公告》（公告编号：2025-060）。 2025年11月26日上午9:00-10:00，公司在上海证券交易所上证路演中心召开了2025年第三季度业绩说明 会，董事长、总经理杜振新先 ...

Company Overview - Zhejiang Shapuaisi Pharmaceutical Co., Ltd. is located in Pinghu City, Zhejiang Province, and was established on July 17, 2000. The company went public on July 2, 2014. Its main business includes the research, production, and sales of eye drops, large-volume injections, and cefuroxime, with revenue composition as follows: 65.84% from product sales, 29.11% from medical services, and 5.05% from other sources [1]. Stock Performance - On November 21, Shapuaisi's stock price fell by 5.04%, closing at 7.72 CNY per share, with a trading volume of 28.37 million CNY and a turnover rate of 0.96%. The total market capitalization is 2.888 billion CNY. The stock has experienced a continuous decline for four days, with a cumulative drop of 4.13% during this period [1]. Shareholder Information - Among the top ten circulating shareholders of Shapuaisi, the Yuanxin Yongfeng Fund has a fund that entered the top ten in the third quarter, holding 2.894 million shares, which accounts for 0.9% of the circulating shares. The estimated floating loss today is approximately 1.1865 million CNY, with a floating loss of 1.0129 million CNY during the four-day decline [2]. Fund Performance - Yuanxin Yongfeng Medical Health A (006274) was established on November 29, 2018, with a current scale of 387 million CNY. Year-to-date returns are 37.08%, ranking 1688 out of 8136 in its category, while the one-year return is 28.45%, ranking 2260 out of 8056. Since its inception, the fund has achieved a return of 131.51% [2]. Fund Manager Information - The fund manager of Yuanxin Yongfeng Medical Health A is Xiao Shiyuan, who has a cumulative tenure of 8 years and 156 days. The total asset scale under his management is 2.272 billion CNY, with the best fund return during his tenure being 137.33% and the worst being 21.37% [2].

Group 1 - The core point of the news is that Chenxin Pharmaceutical's stock price dropped by 5.13% to 19.59 CNY per share, with a trading volume of 279 million CNY and a turnover rate of 3.08%, resulting in a total market capitalization of 8.869 billion CNY [1] - Chenxin Pharmaceutical, established on November 6, 1998, and listed on September 29, 2017, is primarily engaged in the research, development, and production of chemical drug formulations [1] - The company's main revenue sources are: large-volume infusion (42.66%), small-volume injectables (29.80%), oral solid preparations (13.98%), drops (4.31%), lyophilized powder injections (3.68%), ointments (3.43%), raw materials (1.35%), rinsing agents (0.59%), and others (0.20%) [1] Group 2 - Among the top circulating shareholders of Chenxin Pharmaceutical, Ping An Fund's Ping An Medical Health Mixed A (003032) entered the top ten in the third quarter, holding 3.8777 million shares, accounting for 0.86% of the circulating shares, with an estimated floating loss of approximately 4.1104 million CNY [2] - Ping An Medical Health Mixed A (003032) was established on November 24, 2017, with a latest scale of 2.028 billion CNY, achieving a year-to-date return of 63.9% and ranking 315 out of 8138 in its category [2] - The fund manager of Ping An Medical Health Mixed A is Zhou Sicong, who has a cumulative tenure of 11 years and 314 days, with the fund's total asset size at 5.51 billion CNY and a best return of 104.39% during his tenure [3]

Company Overview - Harbin Sanlian Pharmaceutical Co., Ltd. is located in Harbin, Heilongjiang Province, established on June 21, 1996, and listed on September 22, 2017. The company specializes in the research, production, and sales of chemical drug formulations [1][2]. Financial Performance - As of November 10, 2023, Harbin Sanlian reported a revenue of 581 million yuan for the period from January to September 2025, a year-on-year decrease of 30.75%. The net profit attributable to the parent company was -209 million yuan, a significant decline of 614.61% [2]. - The company has cumulatively distributed 677 million yuan in dividends since its A-share listing, with 158 million yuan distributed over the past three years [3]. Stock Performance - On November 18, 2023, Harbin Sanlian's stock price increased by 2.34%, reaching 14.89 yuan per share, with a trading volume of 52.42 million yuan and a turnover rate of 2.05%. The total market capitalization stood at 4.711 billion yuan [1]. - Year-to-date, the stock price has risen by 54.30%, with a 2.69% increase over the last five trading days and a 12.12% increase over the last 20 days. However, it has seen a decline of 1.72% over the past 60 days [1]. Shareholder Information - As of November 10, 2023, the number of shareholders for Harbin Sanlian was 39,600, a decrease of 2.98% from the previous period. The average number of circulating shares per person increased by 3.07% to 4,419 shares [2]. Business Segmentation - The main revenue sources for Harbin Sanlian include: large-volume injections (32.00%), lyophilized powder injections (18.39%), solid preparations (17.39%), small-volume injections (14.34%), and other segments such as veterinary drugs (2.55%) and import/export trade (1.82%) [1].

Core Insights - Huarun Pharmaceutical's stock price remained unchanged on November 17, with a trading volume of 79.44 million yuan [1] - The company experienced a net financing outflow of 2.29 million yuan on the same day, indicating a decrease in investor confidence [1][2] - The company's revenue for the first nine months of 2025 was 976 million yuan, a year-on-year decrease of 9.07%, while net profit dropped by 42.87% to 54.58 million yuan [2] Financing and Margin Trading - On November 17, Huarun Pharmaceutical had a financing buy-in of 4.08 million yuan, with a total financing balance of 234 million yuan, accounting for 5.46% of its market capitalization [1] - The financing balance is below the 50th percentile level over the past year, indicating a relatively low level of leverage [1] - The company had no short selling activity on November 17, with a short selling balance of 0, which is above the 70th percentile level over the past year, suggesting a high level of short selling interest [1] Shareholder Information - As of November 10, the number of shareholders for Huarun Pharmaceutical was 40,100, a decrease of 1.23% from the previous period [2] - The average number of circulating shares per shareholder increased by 1.25% to 29,447 shares [2] Dividend Distribution - Since its A-share listing, Huarun Pharmaceutical has distributed a total of 294 million yuan in dividends, with 49.65 million yuan distributed over the past three years [3]

Group 1 - The stock price of Harbin Sanlian Pharmaceutical Co., Ltd. (哈三联) increased by 2.00% on November 14, reaching 15.29 CNY per share, with a trading volume of 1.51 billion CNY and a turnover rate of 5.70%, resulting in a total market capitalization of 48.37 billion CNY [1] - Year-to-date, the stock price has risen by 58.45%, with a 10.00% increase over the last five trading days, a 16.63% increase over the last 20 days, and a 2.55% increase over the last 60 days [2] - The company has appeared on the "龙虎榜" (a stock market leaderboard) nine times this year, with the most recent appearance on June 3 [2] Group 2 - The company's main business revenue composition includes: large-volume infusion (32.00%), lyophilized powder injection (18.39%), solid preparations (17.39%), small-volume injections (14.34%), and others [2] - As of November 10, the number of shareholders is 39,600, a decrease of 2.98% from the previous period, while the average circulating shares per person increased by 3.07% to 4,419 shares [2] - For the period from January to September 2025, the company reported a revenue of 581 million CNY, a year-on-year decrease of 30.75%, and a net profit attributable to shareholders of -209 million CNY, a year-on-year decrease of 614.61% [2] Group 3 - Since its A-share listing, the company has distributed a total of 677 million CNY in dividends, with 158 million CNY distributed over the past three years [3]

Group 1 - The core viewpoint of the news is that Huaren Pharmaceutical's stock performance and financing activities indicate a stable but cautious market position, with significant changes in revenue and profit margins reported in recent financial results [1][2]. Group 2 - As of October 23, Huaren Pharmaceutical's stock price remained unchanged at 0.00%, with a trading volume of 60.76 million yuan. The financing buy-in amount was 9.08 million yuan, while the financing repayment was 11.02 million yuan, resulting in a net financing buy-in of -1.94 million yuan [1]. - The total balance of margin trading for Huaren Pharmaceutical reached 256 million yuan, accounting for 6.35% of its market capitalization, which is above the 60th percentile level over the past year, indicating a relatively high financing level [1]. - The company has not engaged in any short selling activities on October 23, with no shares sold or repaid, and the short selling balance also stood at zero [1]. - Huaren Pharmaceutical's main business revenue composition includes: basic infusion (40.63%), peritoneal dialysis fluid (34.90%), therapeutic preparations (14.92%), medical devices (8.14%), and others (1.41%) [1]. Group 3 - As of October 10, the number of shareholders for Huaren Pharmaceutical was 40,700, an increase of 0.49% from the previous period, while the average circulating shares per person decreased by 0.49% to 29,013 shares [2]. - For the first half of 2025, Huaren Pharmaceutical reported a revenue of 624 million yuan, a year-on-year decrease of 19.13%, and a net profit attributable to shareholders of 37.33 million yuan, down 49.01% year-on-year [2]. Group 4 - Since its A-share listing, Huaren Pharmaceutical has distributed a total of 294 million yuan in dividends, with cumulative distributions of 49.65 million yuan over the past three years [3].

Core Viewpoint - Chenxin Pharmaceutical has shown significant stock price appreciation this year, with a year-to-date increase of 85.19% and notable recent trading activity, indicating strong market interest and potential investment opportunities [1][2]. Group 1: Stock Performance - As of October 23, Chenxin Pharmaceutical's stock price reached 24.69 CNY per share, with a trading volume of 5.84 billion CNY and a turnover rate of 5.28%, resulting in a total market capitalization of 111.78 billion CNY [1]. - The stock has experienced a 16.74% increase over the last five trading days, a 17.45% increase over the last 20 days, and a 20.78% increase over the last 60 days [1]. - The company has appeared on the "Dragon and Tiger List" five times this year, with the most recent appearance on October 17, where it recorded a net purchase of 1.29 billion CNY [1]. Group 2: Company Overview - Chenxin Pharmaceutical, established on November 6, 1998, and listed on September 29, 2017, is located in Jining, Shandong Province, and specializes in the research, development, and production of chemical drug formulations [2]. - The company's revenue composition includes: large-volume injections (42.66%), small-volume injections (29.80%), oral solid preparations (13.98%), and other formulations [2]. - As of June 30, the number of shareholders increased by 68.07% to 35,900, while the average circulating shares per person decreased by 40.50% to 12,602 shares [2]. Group 3: Financial Performance - For the first half of 2025, Chenxin Pharmaceutical reported a revenue of 1.74 billion CNY, a year-on-year decrease of 15.97%, and a net profit attributable to shareholders of 229 million CNY, down 15.23% year-on-year [2]. - The company has distributed a total of 1.197 billion CNY in dividends since its A-share listing, with 633 million CNY distributed over the past three years [3]. - As of June 30, 2025, Hong Kong Central Clearing Limited was the seventh-largest circulating shareholder, increasing its holdings by 196.89 million shares [3].